CYFRA 21-1 External Quality Assessment

The RIQAS CYFRA 21-1 EQA programme is designed to cover the analysis of CYFRA 21-1 in clinical laboratories when monitoring the response to treatment of cancers such as non-small cell lung carcinoma, cervical, breast and bladder cancer.

  • Lyophilised samples
  • Monthly reporting
  • Testing covers the full range of clinically relevant decision levels
  • Submit results and view reports online via RIQAS.net
  • 12 month subscription

Not accredited to ISO/IEC 17043

Cat NoKit SizeFrequencyCycle StartParameters 
RQ917512 x 1mlMonthlyMarch1

[ddownload class="button tiny secondary" id="8275" text="Enrolment Document"]

[ddownload class="button tiny secondary" id="8276" text="Method Questionnaire"]

[ddownload class="button tiny secondary" id="2976" text="Instrument & Reagent Codes"]


Parameter

  • CYFRA 21-1 (Cytokeratin 19)
Clinical Laboratory Survey